Home Healthcare Medical Devices Interventional Oncology Devices Market

Interventional Oncology Devices Market Size, Share & Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Other Cancers), By Product Type (Ablation Devices, Embolization Devices, Supporting Devices, Next-Generation Devices), By End-User (Hospitals, Ambulatory Surgery Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Anantika Sharma | Format: | Report Code: SR4197DR | Pages: 156
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Interventional Oncology Devices Market, By Cancer Type 2022-2034 (USD MILLION/ Units)
    1. Liver Cancer
    2. Lung Cancer
    3. Kidney Cancer
    4. Prostate Cancer
    5. Other Cancers
  2. Interventional Oncology Devices Market, By Product Type 2022-2034 (USD MILLION/ Units)
    1. Ablation Devices
    2. Embolization Devices
    3. Supporting Devices
    4. Next-Generation Devices
  3. Interventional Oncology Devices Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Ambulatory Surgery Centers
    3. Others
  4. Regional Interventional Oncology Devices Market
    1. North America
      1. North America Interventional Oncology Devices Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
      2. North America Interventional Oncology Devices Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Ablation Devices
        2. Embolization Devices
        3. Supporting Devices
        4. Next-Generation Devices
      3. North America Interventional Oncology Devices Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgery Centers
        3. Others
      4. U.S.
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      5. Canada
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
    2. Europe
      1. Europe Interventional Oncology Devices Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
      2. Europe Interventional Oncology Devices Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Ablation Devices
        2. Embolization Devices
        3. Supporting Devices
        4. Next-Generation Devices
      3. Europe Interventional Oncology Devices Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgery Centers
        3. Others
      4. U.K.
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      5. Germany
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      6. France
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      7. Spain
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      8. Italy
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      9. Russia
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      10. Nordic
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      11. Benelux
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      12. Rest of Europe
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
    3. APAC
      1. APAC Interventional Oncology Devices Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
      2. APAC Interventional Oncology Devices Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Ablation Devices
        2. Embolization Devices
        3. Supporting Devices
        4. Next-Generation Devices
      3. APAC Interventional Oncology Devices Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgery Centers
        3. Others
      4. China
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      5. Korea
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      6. Japan
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      7. India
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      8. Australia
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      9. Taiwan
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      10. South East Asia
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      11. Rest of Asia-Pacific
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Interventional Oncology Devices Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
      2. Middle East and Africa Interventional Oncology Devices Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Ablation Devices
        2. Embolization Devices
        3. Supporting Devices
        4. Next-Generation Devices
      3. Middle East and Africa Interventional Oncology Devices Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgery Centers
        3. Others
      4. UAE
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      5. Turkey
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      6. Saudi Arabia
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      7. South Africa
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      8. Egypt
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      9. Nigeria
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      10. Rest of MEA
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
    5. LATAM
      1. LATAM Interventional Oncology Devices Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
      2. LATAM Interventional Oncology Devices Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Ablation Devices
        2. Embolization Devices
        3. Supporting Devices
        4. Next-Generation Devices
      3. LATAM Interventional Oncology Devices Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgery Centers
        3. Others
      4. Brazil
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      5. Mexico
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      6. Argentina
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      7. Chile
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      8. Colombia
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
      9. Rest of LATAM
        1. Liver Cancer
        2. Lung Cancer
        3. Kidney Cancer
        4. Prostate Cancer
        5. Other Cancers
        6. Ablation Devices
        7. Embolization Devices
        8. Supporting Devices
        9. Next-Generation Devices
        10. Hospitals
        11. Ambulatory Surgery Centers
        12. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.